Research shows the success of a bacterial community depends on its shape.
Raymond V. Gilmartin, the chairman, president and CEO of Merck & Co., Inc., will share his views on the impacts of the health care revolution on Tuesday, March 3 at 4pm in Wong Auditorium (Tang Center, Building E51).
The 90-minute presentation and discussion, entitled "The Health Care Revolution and its Impact on Pharmaceutical Innovation," is part of the Industry Leaders in Technology and Management lecture series, co-sponsored by the School of Engineering and the Sloan School of Management and hosted by the Center for Technology, Policy and Industrial Development.
Mr. Gilmartin has 22 years of experience as a health care industry executive, having worked at Eastman Kodak and Arthur D. Little before serving as vice president for corporate planning (1976) and president (1987) of Becton Dickinson and Co. When he left in 1994, he was also chairman and CEO. In 1994, Mr. Gilmartin joined Merck as president and CEO, and added the role of chairman later that year. He holds the the BS in electrical engineering from Union College (1963) and the MBA from Harvard University (1968).
Merck, a pharmaceutical products and services company, has divisions including human health, managed pharmaceutical care, manufacturing, research and vaccines. Its 1997 sales were $23.6 billion, with net income of $4.6 billion. Approximately $1.7 billion was invested in R&D.
Merck and MIT are in the first stage of a long-term research and education collaboration to pursue joint initiatives in science and engineering. As part of this collaboration, Merck supports a group of 18 scholars through the MIT-Merck Fellowship Program.
Mr. Gilmartin's lecture is open to the MIT community. Seating is limited to a first-come, first-served basis. For more information, call x3-0404 or refer to the CTPID home page.
A version of this article appeared in MIT Tech Talk on February 25, 1998.